Abstract:Background: Psychiatric disorders impose a huge health and economic burden on modern society. However, there is currently no proven disease-modifying treatment available, partly owing to the inefficiency of drug target identification and validation. Here, we aim to identify therapeutic targets relevant to psychiatric disorders by conduct a Mendelian randomization (MR) analysis.Methods: We performed a genome-wide MR analysis by integrating expression quantitative trait loci (eQTL) of 4,479 actionable genes that encode druggable proteins and genetic summary statistics from genome-wide association studies (GWASs) of psychiatric disorders. Furthermore, we conducted colocalization analysis on the top MR findings (after sensitivity analysis) to confirm the sharing of the same causal variants between gene expression and trait in each genomic region. We then employed protein quantitative trait loci (pQTL) data as genetic proposed instruments for intersected the colocalized genes to provide further genetic evidence.Findings: By focusing on druggable eQTL genetic instruments in MR analysis, we obtained 19 promising drug targets for psychiatric disorders, including 12 significant genes for schizophrenia, four significant genes for bipolar disorder, two significant genes for depression, and one significant gene for attention deficit and hyperactivity. Combining MR results using pQTL genetic instruments, we finally proposed two drug-targeting genes (ACE and NEK4) with schizophrenia, one gene (NEK4) with bipolar disorder, and one gene (TIE1) with attention deficit and hyperactivity, which are supported by the strongest MR evidence. Interpretation: This work revealed that drug-targeting ACE, NEK4 and TIE1 with genetic support were more likely to be to succeed in clinical trials. In addition, our study prioritizes approved drug targets for the development of new therapies and provides critical drug reuse opportunities for psychiatric disorders.Funding: This work was supported by the grant from the National Natural Science Foundation of China (82101611, 11835014, 62072003) and the National Key Research and Development Program of China (2020YFA0908700).Declaration of Interest: There are no conflicts of interest to declare.

Unraveling NEK4 As a Potential Drug Target in Schizophrenia and Bipolar I Disorder: A Proteomic and Genomic Approach.

Chromatin Profiling in Human Neurons Reveals Aberrant Roles for Histone Acetylation and BET Family Proteins in Schizophrenia

Independent replications and integrative analyses confirm TRANK1 as a susceptibility gene for bipolar disorder

Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders

Revealing Potential Drug Targets in Schizophrenia Through Proteome-Wide Mendelian Randomization Genetic Insights

F206. A TRANSLATIONAL STUDY OF BEHAVIOR, BRAIN STRUCTURE AND GENE PATHWAY IN ERBB4 KNOCKOUT MICE AND FIRST-EPISODE TREATMENT-NAïVE PATIENTS WITH SCHIZOPHRENIA

Identifying novel proteins underlying bipolar disorder via integrating pQTLs of the plasma, CSF, and brain with GWAS summary data

Dissecting the Association Between Psychiatric Disorders and Neurological Proteins: a Genetic Correlation and Two-Sample Bidirectional Mendelian Randomization Study.

NEK4 modulates circadian fluctuations of emotional behaviors and synaptogenesis in male mice

Genome-Wide Mendelian Randomization Reveals Genetically-Supported Drug Targets for Psychiatric Disorders

Genome-Transcriptome-Functional Connectivity-Cognition Link Differentiates Schizophrenia from Bipolar Disorder

Mendelian Randomization Using the Druggable Genome Reveals Genetically Supported Drug Targets for Psychiatric Disorders.

Genetic associations between bipolar disorder and brain structural phenotypes

Identifying crucial biomarkers in peripheral blood of schizophrenia and screening therapeutic agents by comprehensive bioinformatics analysis

Transcriptomic and epigenomic consequences of heterozygous loss of function mutations in , the first large-effect shared risk gene for bipolar disorder and schizophrenia

Multivariate analysis reveals genetic associations of the resting default mode network in psychotic bipolar disorder and schizophrenia.

Toward Drug Targets and Neuroimaging Biomarkers for Neuropsychiatric Disorders

Proteome-wide Association Study Provides Insights Into the Genetic Component of Protein Abundance in Psychiatric Disorders

Integrated Transcriptome Analysis Reveals Novel Molecular Signatures for Schizophrenia Characterization.

A Hypothesis-Driven Pathway Analysis Reveals Myelin-Related Pathways That Contribute to the Risk of Schizophrenia and Bipolar Disorder.

Novel Gene-Brain Structure Relationships in Psychotic Disorder Revealed Using Parallel Independent Component Analyses.